23:43 , Nov 12, 2018 |  BC Extra  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
18:19 , Nov 9, 2018 |  BC Week In Review  |  Company News

Novartis teases prices of gene therapy, IL-1β mAb as game-changer

During its R&D day Nov. 5, Novartis AG (NYSE:NVS; SIX:NOVN) hinted at a multimillion dollar price tag for its gene therapy AVXS-101, and also discussed plans to disrupt the non-small cell lung cancer (NSCLC) landscape...
00:32 , Nov 6, 2018 |  BC Extra  |  Company News

Novartis teases price of gene therapy, IL-1β mAb as game-changer

During its R&D day Monday, Novartis AG (NYSE:NVS; SIX:NOVN) hinted at a multimillion dollar price tag for its gene therapy AVXS-101, and also discussed plans to disrupt the non-small cell lung cancer (NSCLC) landscape that...
18:21 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Immune Design deprioritizes synovial sarcoma compound CMB305

Immune Design Corp. (NASDAQ:IMDZ) discontinued the Phase III SYNOVATE trial of CMB305 monotherapy to treat synovial sarcoma after an early analysis of a Phase II trial in the indication showed that CMB305 in combination with...
20:48 , Oct 5, 2018 |  BC Week In Review  |  Company News

Roche gains CD25 program via Tusk takeout

Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to receive €585 million ($686.8 million) in undisclosed milestones. Roche will gain...
20:00 , Oct 5, 2018 |  BC Week In Review  |  Company News

Immutep, Merck KGgA, Pfizer partner for Phase I immunotherapy combo trial

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP), Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) partnered to test Immutep's eftilagimod alpha (IMP321) in combination with the pharmas' anti-PD-L1 mAb Bavencio avelumab in a Phase I trial for patients with...
21:32 , Sep 28, 2018 |  BC Extra  |  Company News

Roche gains CD25 program via Tusk takeout

Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to receive €585 million ($686.8 million) in undisclosed milestones. Roche will gain...
17:24 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Genentech's immunotherapy improves survival by two months in first-line SCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower133 trial showing that its anti-PD-L1 mAb Tecentriq atezolizumab in combination with chemotherapy led to a two-month overall survival (OS)...
20:47 , Sep 25, 2018 |  BC Extra  |  Clinical News

Genentech's immunotherapy improves survival by two months in first-line SCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower133 trial showing that its anti-PD-L1 mAb Tecentriq atezolizumab in combination with chemotherapy led to a two-month overall survival (OS)...
19:15 , Sep 14, 2018 |  BC Week In Review  |  Company News

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI will facilitate the trial,...